Presentation by two of the authors, Maureen Cropper and Stephen Hutton, on international cooperation to mitigate a pandemic: 1) Is it cost-effective for wealthy nations to pay for the purchase and distribution of antivirals (or vaccines) in the outbreak source country or other poor countries so as to slow the spread of the pandemic?
2) What global allocation rules are most effective in reducing the number of cases and in reducing the aggregate economic impact?
In the case where treatment with antiviral drugs alone can be used to contain a potential pandemic, there is an obvious case for wealthy nations to pay for pandemic containment. But what about the case where a pandemic cannot be detected early enough or treatment is not effective enough for containment to be possible? Pandemic epidemiology involves two types of externalities that suggest that it might be in the selfinterest of wealthy countries to fund such a scheme. They found that there are benefits to rich countries from donating antivirals to poor countries. These benefits are modest, but real. 
